Targeting c-MET in the battle against advanced nonsmall-cell lung cancer

Combined EGFR/MET or EGFR/HSP90 Inhibition Is Effective in the Treatment of Lung Cancers Codriven by Mutant EGFR Containing T790M and MET

(2012) L. Xu et al.   CANCER RESEARCH

Targeting the Hepatocyte Growth Factor–cMET Axis in Cancer Therapy

(2012) George R. Blumenschein et al.   JOURNAL OF CLINICAL ONCOLOGY

Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial

(2012) Vincent A Miller et al.   LANCET ONCOLOGY

Afatinib for patients with lung adenocarcinoma and epidermal growth factor receptor mutations (LUX-Lung 2): a phase 2 trial

(2012) James Chih-Hsin Yang et al.   LANCET ONCOLOGY

MET Signaling Pathway: A Rational Target for Cancer Therapy

(2011) Leonard J. Appleman   JOURNAL OF CLINICAL ONCOLOGY

Randomized Phase II Study of Erlotinib Plus Tivantinib Versus Erlotinib Plus Placebo in Previously Treated Non–Small-Cell Lung Cancer

(2011) Lecia V. Sequist et al.   JOURNAL OF CLINICAL ONCOLOGY

Cabozantinib (XL184), a Novel MET and VEGFR2 Inhibitor, Simultaneously Suppresses Metastasis, Angiogenesis, and Tumor Growth

(2011) F. M. Yakes et al.   MOLECULAR CANCER THERAPEUTICS

A phase II study evaluating the efficacy and safety of AMG 102 (rilotumumab) in patients with recurrent glioblastoma

(2011) P. Y. Wen et al.   NEURO-ONCOLOGY

Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors

(2011) L. V. Sequist et al.   Science Translational Medicine

C-MET as a new therapeutic target for the development of novel anticancer drugs

(2010) Israel Cañadas et al.   Clinical & Translational Oncology

Clinical implications ofMETgene copy number in lung cancer

(2010) Luca Toschi et al.   Future Oncology

Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer

(2010) Eunice L. Kwak et al.   NEW ENGLAND JOURNAL OF MEDICINE

Ethnic Differences and Functional Analysis of MET Mutations in Lung Cancer

(2009) S. Krishnaswamy et al.   CLINICAL CANCER RESEARCH

Novel Therapeutic Inhibitors of the c-Met Signaling Pathway in Cancer

(2009) J. P. Eder et al.   CLINICAL CANCER RESEARCH

IncreasedMETGene Copy Number Negatively Affects Survival of Surgically Resected Non–Small-Cell Lung Cancer Patients

(2009) Federico Cappuzzo et al.   JOURNAL OF CLINICAL ONCOLOGY

Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial

(2009) Robert Pirker et al.   LANCET

Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma

(2009) Tony S. Mok et al.   NEW ENGLAND JOURNAL OF MEDICINE

Clinicopathologic and Molecular Features of Epidermal Growth Factor Receptor T790M Mutation and c-MET Amplification in Tyrosine Kinase Inhibitor-resistant Chinese Non-small Cell Lung Cancer

(2009) Hua-Jun Chen et al.   PATHOLOGY & ONCOLOGY RESEARCH

MET increased gene copy number and primary resistance to gefitinib therapy in non-small-cell lung cancer patients

(2008) F. Cappuzzo et al.   ANNALS OF ONCOLOGY

MetMAb, the One-Armed 5D5 Anti-c-Met Antibody, Inhibits Orthotopic Pancreatic Tumor Growth and Improves Survival

(2008) H. Jin et al.   CANCER RESEARCH

Met gene copy number predicts the prognosis for completely resected non-small cell lung cancer

(2008) Katsuhiro Okuda et al.   CANCER SCIENCE

MET as a target for treatment of chest tumors

(2008) Nicole A. Cipriani et al.   LUNG CANCER

NK4 gene therapy targeting HGF-Met and angiogenesis

(2007) Kunio Matsumoto   Frontiers in Bioscience-Landmark